论文部分内容阅读
目的对 DRV型脂质体作为免疫佐剂的可行性及稳定性进行研究。方法改良的 DRV型脂质体的制备 ;并用EL ISA、MTT法、皮肤迟发型过敏反应 ( DTH)及整体的抑瘤试验 ;TBA法、碘值、氧化指数和气质联用分析法进行鉴定。结果1DRV型脂质体能增强小鼠对抗原 (粘液糖蛋白、核心多肽及基因肽 )的体液免疫和细胞免疫 ;疫苗免疫后 C5 7小鼠有杀瘤作用 (对照组 89%成瘤 ,疫苗组为 40 % )。2 DRV型脂质体在低温、密闭、避光条件下储存 ,稳定期在 1年以上。结论 DRV型脂质体能增强机体对抗原的体液免疫和细胞免疫 ,可作为肿瘤疫苗的免疫佐剂
Objective To study the feasibility and stability of DRV liposome as an adjuvant. Methods The improved DRV liposomes were prepared and identified by EL ISA, MTT assay, skin delayed hypersensitivity (DTH) and tumor inhibition test as a whole, TBA method, iodine value, oxidation index and GC-MS analysis. Results 1The DRV liposomes enhanced humoral and cellular immunity to murine antigens (mucoglycoproteins, core polypeptides, and gene peptides); C57 mice had tumoricidal effects after immunization with vaccines (control group, 89% tumorigenesis, vaccine group 40%). 2 DRV-type liposomes were stored at low temperature, confined and protected from light, and the stability period was more than 1 year. Conclusion DRV-type liposomes can enhance humoral and cellular immunity to antigens and can be used as an adjuvant for tumor vaccines.